Navigation Links
Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

liver, lung and lymph node metastases. The duration of response, independently reviewed, ranged from 7.1 weeks to 30.0 weeks. The median time to progression in the treated population was 5.9 weeks. The adverse events were manageable, predictable and consistent with those seen in the Phase I trials of ispinesib. The most common grade 3/4 adverse events observed were neutropenia, febrile neutropenia and neutropenic sepsis.

In addition, GSK has sponsored three dose-escalating Phase Ib clinical trials. Each of these clinical trials was designed to evaluate the safety, tolerability and pharmacokinetics of ispinesib in combination with a leading anti-cancer therapeutic, one in combination with carboplatin, the second in combination with capecitabine, and the third in combination with docetaxel. The clinical trial evaluating ispinesib in combination with capecitabine is closed to enrollment. Final data from this trial are expected in 2007.

Under a November 2006 amendment to its collaboration and license agreement with GSK, Cytokinetics has assumed responsibility for the costs and activities associated with the continued development of the KSP inhibitors, ispinesib and SB-743921, subject to GSK s option to resume responsibility for some or all development and commercialization activities associated with each of these novel drug candidates. Cytokinetics plans to conduct, at its expense, a focused development program for ispinesib in breast cancer specifically designed to supplement the broad series of Phase I and Phase II clinical trials sponsored by GSK that have demonstrated clinical activity in the treatment of patients with metastatic breast cancer and that have shown an acceptable tolerability profile for ispinesib in combination with standard chemotherapeutics.

The NCI has sponsored six additional Phase II clinical trials, evaluating the potential efficacy of ispinesib in an array of different tumor types. Enrollment has been closed for
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:11/26/2014)... Nov. 26, 2014  Cohen, Placitella & Roth, ... investors who purchased Nymox Pharmaceutical Corporation ("Nymox" or ... period from January 31, 2011 through November 2, ... and certain of its officers and directors publically ... of Sections 10(b) and 20(a) of the Securities ...
(Date:11/26/2014)... 2014   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today announced ... CEO of Regulus, will present a company overview at ... at the New York Palace Hotel on Wednesday, December ... be webcast at the time of the presentation and ...
(Date:11/26/2014)... -- Investor-Edge has initiated coverage on the following ... PLC (NASDAQ: HZNP ), Endocyte Inc. (NASDAQ: ... ), and Theravance Inc. (NASDAQ: THRX ). Free ... http://investor-edge.com/register . On Tuesday, November 25, 2014, the ... Industrial Average edged 0.02% lower, to finish the day at ...
Breaking Medicine Technology:Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5
... UBM Canon Medical Device Media Group,s ... the " Technological Advances in Implantable Devices " virtual event ... 5 p.m. Eastern.  The event is dedicated to cutting-edge trends ... conference and trade show offers the opportunity to learn from ...
... N.J., Feb. 1, 2011 Soligenix, Inc. (OTC Bulletin ... a late-stage biopharmaceutical company, announced today that it has ... and Chief Medical Officer. Dr. Horgan is a board-certified ... experience in the care of patients with inflammatory bowel ...
Cached Medicine Technology:UBM Studios Virtual Event Connects the UBM Canon Medical Device Media Group with the Medical Device Design Community 2UBM Studios Virtual Event Connects the UBM Canon Medical Device Media Group with the Medical Device Design Community 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4
(Date:11/28/2014)... November 29, 2014 BambooFlooringChina.com has been ... bamboo industry. Recently, the business has announced its new ... is offering big discount on these new models. , ... scraped by hands, without carpenter machines involved. It is ... It is great for do-it-yourselfers without hard work on ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Now that ... http://www.rustysautosalvage.com ), one of the nation's leading cash-for-junk-cars companies, ... salvage vehicles to be more competitive and help bring ... during this festive time of year. , Along with ... owners across the US also deal with large travel ...
(Date:11/28/2014)... Dr. Diane Walder, one of the ... addition of Dr. Bridgit Nolan to her practice as ... having completed her dermatology residency at the University of ... Dr. Nolan to join her practice because ... dermatology. Not only does Dr. Nolan strive to provide ...
(Date:11/28/2014)... Gables, Florida (PRWEB) November 28, 2014 ... Thanksgiving, Turbana and Sendik’s will present Feeding America Eastern ... with Sendik’s Food Market to donate a portion of ... participated in Sendik’s promotion, “7 Days, 7 Ways to ... throughout fall, Fyffes pineapples were two for $4 and ...
(Date:11/28/2014)... Dr. Andrew Campbell, one of the ... of Quintessa Aesthetic Center into a third location in ... N1497 Golf Road in Suite 200 and will open ... new Delafield location will offer a variety of ... filler injectables , micro laser peels, chemical peels, ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com Introduces Its New Strand Woven Bamboo Flooring Collection 2Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Dr. Diane Walder Welcomes New Cosmetic Dermatologist to Practice 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 3Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2
... heart’s electrical system, which can be inherited or acquired. The ... an electrocardiogram. People with LQTS are prone to develop an ... or loud noise. This improper rhythm interferes with blood flow ... arrest. A new study shows a specific surgery can reduce ...
... Latest researcher show that a few alcoholic beverages a ... disease in men // with high blood pressure. ... had a significantly lower risk of death by nearly ... a reduced risk of cardiovascular disease death as alcohol ...
... study , Asian investigators suggest physicians should not recommend ... ,A therapy routinely given to newborns to prevent or ... and cognitive functioning by school age.Previous research shows dexamethasone, ... in the short-term and allows for early weaning from ...
... of developing breast cancer are not taking a drug that can ... ,Results of the study showed , postmenopausal women over age 50 ... look abnormal or are diagnosed with abnormal cells in the lobules ... to be offered and accept the use of tamoxifen. Worldwide data ...
... pregnancy is just as harmful to kids as is ... long-term smoke exposure in the womb and after birth ... first 10 years.Researchers studied the effect of smoke exposure ... of the children were at “high risk” for allergies. ...
... Fatigue is the most frequent and distressing problem related ... living and has profound // effects on a patient’s ... months or years. New research finds energy conservation and ... going through drug therapy. ,Energy conservation is ...
Cached Medicine News:
... The Series I Instrument program offers state-of-the-art ... profile, while maintaining strength and durability. Low ... in tight joint spaces. Series I instruments ... tip style, size and angle required for ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
Medicine Products: